Concord Biotech
CONCORDBIO
Pharma₹1399.00
price as of 3/10/2026, 12:12:59 am
Market cap ₹14,636 Cr
- P/E
- 48.27
- Day range
- ₹1,320.00 – ₹1,400.00
- 52-week range
- ₹987.00 – ₹1,647.80
- Volume
- 1.47 L
- Open
- ₹1,373.60
- Prev close
- ₹1,373.60
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
CONCORDBIO in NSE indices and F&O
Research profile
Derived metrics
- Earn. yield
- 2.1%
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 44 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹432.1K Cr | 35.71 | 5.18 | 14.8% | 21.0% | 29.0% | 0.06 | +10.5% |
| Divi's LaboratoriesDIVISLAB | ₹245.5K Cr | 83.82 | 14.66 | 16.2% | 22.0% | 41.0% | 0.00 | +27.8% |
| Torrent PharmaTORNTPHARM | ₹181.3K Cr | 76.11 | 19.22 | 26.8% | 15.0% | 34.0% | 1.79 | +54.8% |
| Apollo HospitalsAPOLLOHOSP | ₹116.9K Cr | 56.14 | 13.60 | 22.6% | 17.0% | 16.0% | 0.90 | +20.6% |
| Zydus LifesciencesZYDUSLIFE | ₹114.3K Cr | 25.57 | 4.26 | 20.1% | 21.0% | 24.0% | 0.46 | +22.0% |
| CiplaCIPLA | ₹108.6K Cr | 32.26 | 3.20 | 11.8% | 15.0% | 17.0% | 0.02 | +2.3% |
| Laurus LabsLAURUSLABS | ₹107.2K Cr | 98.02 | 20.20 | 18.2% | 18.0% | 32.0% | 0.48 | +29.0% |
| Concord BiotechCONCORDBIO | ₹14.6K Cr | 48.27 | — | — | — | — | — | — |
| Sector median | ₹45.8K Cr | 49.95 | 5.80 | 14.6% | 16.0% | 22.5% | 0.31 | +17.1% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Financials not yet synced
This company is tracked, but its filings have not been processed yet. Results appear here once the next sync reaches it.
Corporate actions
No dividends, splits or bonuses recorded for this company yet.
FAQ
Concord Biotech: common questions
Answered from the figures on this page.
Concord Biotech last traded at ₹1,399.00 (NSE, as of 3 Oct 2026). The last session moved it up 1.85%.
Concord Biotech is valued at about ₹14,636 crore (NSE, as of 3 Oct 2026).
Concord Biotech trades at a price-to-earnings ratio of 48.27 (NSE, as of 3 Oct 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.
Concord Biotech has traded between ₹987.00 and ₹1,647.80 over the past 52 weeks, to 3 Oct 2026. It is currently 62% of the way up that range.
Concord Biotech (CONCORDBIO) is classified under Pharma on this site's screener.
